PresentationArthur SandsCEO, President & Director Good morning, and welcome to the Nurix Therapeutics Conference Call. I'm Arthur Sands, President and CEO. And I'm joined today on this call by Gwenn Hansen, our Chief Scientific Officer; Paula O'Connor, our Chief Medical Officer; and Hans Van Houte, our Chief Financial Officer. These are our disclaimers. At Nurix, we're advancing a pipeline of innovative targeted protein degrader drugs in oncology and inflammation and immunology or I&I, each with best-in-cl ...